Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title: An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
In brief: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.
Ages eligible: 18 Years to 65 Years
Locations: Aclaris Investigator Site
- Encinitas, California, United States, 92024
- Los Angeles, California, United States, 90036
- Worcester, Massachusetts, United States, 01655
- Dallas, Texas, United States, 75390
- Lynchburg, Virginia, United States, 24501
Status: Unknown, not recruiting
Start date: March 19, 2018
Completion date: September 30, 2019
Identifier: ClinicalTrials.gov NCT03468855
Contacts: To learn more about this study, you or your doctor may contact Aclaris Therapeuitcs. Please refer to this study by its NCT number.
- How can I explain vitiligo to my children?
Vitiligo can be puzzling for a child because a person who has it isn't "ill" in a common sense. To choose the right words to explain vitiligo diagnosis to a child, first consi...
- What causes vitiligo?
Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...
- What is the best therapy for localized vitiligo?
An investigation from Egypt cites early systemic immunomodulation for recent localized vitiligo as a “successful approach” for achieving early control of disease activity. It he...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.